Skip to main content
. 2012 Jun 22;9:62. doi: 10.1186/1743-7075-9-62

Table 1.

Profile of major fatty acids, at baseline and with rosiglitazone

Fatty Acids Percent of Total (%)
 
Control
SGA
Fatty Acid
Baseline
Rosiglitazone
Baseline
Rosiglitazone
Palmitate 16:0
36.4 ± 1.5
37.9 ± 1.1
37.5 ± 0.7
37.7 ± 2.4
Palmitoleate 16:1n-7
3.4 ± 0.1
3.09 ± 0.04
3.4 ± 0.1
3.3 ± 0.3
Stearate 18:0
22.6 ± 0.9
29.1 ± 0.9*
20.8 ± 0.6
22.4 ± 1.4c
Oleate 18:1n-9
19.7 ± 0.7
17.4 ± 0.4
20.0 ± 0.3
20.1 ± 1.2
Vaccenate 18:1n-7 12.0 ± 0.5 10.4 ± 0.2 13.2 ± 0.3 12.1 ± 0.9

Cp < 0.05 compared with Control receiving the same treatment.

*p < 0.05 compared to the untreated state within the same group.

The fatty acid percentages of total are presented as the mean ± the standard error of the mean (SEM). With rosiglitazone treatment, Controls demonstrated increased stearate abundance.